Published • loading... • Updated
Madrigal Licenses Arrowhead Drug Candidate for MASH
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Madrigal Licenses Arrowhead Drug Candidate for MASH
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) licensed a clinical-stage gene-silencing therapy from Arrowhead Pharmaceuticals to expand its pipeline of treatments for metabolic dysfunction-associated steatohepatitis, or MASH, including patients with a genetic mutation linked to more severe liver disease progression. The agreement gives Madrigal exclusive global rights to develop, manufacture, and commercialize ARO-PNPLA3, a small in…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
